Published in J Neurovirol on July 01, 2005
Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One (2008) 3.85
Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis (2012) 2.37
CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS (2011) 2.31
Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS (2011) 2.04
Neurologic disease burden in treated HIV/AIDS predicts survival: a population-based study. Neurology (2010) 1.97
Metabolomic analysis of the cerebrospinal fluid reveals changes in phospholipase expression in the CNS of SIV-infected macaques. J Clin Invest (2008) 1.66
Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder. Neurology (2012) 1.48
Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection. J Acquir Immune Defic Syndr (2012) 1.44
HIV DNA and cognition in a Thai longitudinal HAART initiation cohort: the SEARCH 001 Cohort Study. Neurology (2009) 1.41
Pattern of neuropsychological performance among HIV positive patients in Uganda. BMC Neurol (2007) 1.35
HIV DNA in circulating monocytes as a mechanism to dementia and other HIV complications. J Leukoc Biol (2010) 1.24
Central nervous system immune reconstitution inflammatory syndrome. Curr Infect Dis Rep (2013) 1.21
Neurocognitive effects of HIV, hepatitis C, and substance use history. J Int Neuropsychol Soc (2011) 1.15
Risk factors for HIV-associated neurocognitive disorders (HAND) in sub-Saharan Africa: the case of Yaoundé-Cameroon. J Neurol Sci (2009) 1.07
Update on HIV-associated neurocognitive disorders. Curr Neurol Neurosci Rep (2013) 0.99
Cognitive impairment in patients with AIDS - prevalence and severity. HIV AIDS (Auckl) (2015) 0.96
Parallel high throughput neuronal toxicity assays demonstrate uncoupling between loss of mitochondrial membrane potential and neuronal damage in a model of HIV-induced neurodegeneration. Neurosci Res (2011) 0.93
Lessons learned developing a diagnostic tool for HIV-associated dementia feasible to implement in resource-limited settings: pilot testing in Kenya. PLoS One (2012) 0.93
CCL3 genotype and current depression increase risk of HIV-associated dementia. Neurobehav HIV Med (2009) 0.93
Neuroimaging biomarkers of neurodegenerative diseases and dementia. Semin Neurol (2013) 0.92
Biomarkers of neurological status in HIV infection: a 3-year study. Proteomics Clin Appl (2010) 0.92
The role of host genetics in the susceptibility for HIV-associated neurocognitive disorders. AIDS Behav (2008) 0.91
Brain dysfunction in the era of combination antiretroviral therapy: implications for the treatment of the aging population of HIV-infected individuals. Curr Opin Investig Drugs (2010) 0.91
HIV-associated neurocognitive disorders: the relationship of HIV infection with physical and social comorbidities. Biomed Res Int (2015) 0.89
Human immunodeficiency virus-1 protein Tat induces excitotoxic loss of presynaptic terminals in hippocampal cultures. Mol Cell Neurosci (2012) 0.89
Host and viral factors influencing the pathogenesis of HIV-associated neurocognitive disorders. J Neuroimmune Pharmacol (2009) 0.89
Applications and limitations of inflammatory biomarkers for studies on neurocognitive impairment in HIV infection. J Neuroimmune Pharmacol (2013) 0.88
Dopamine receptor D3 genetic polymorphism (rs6280TC) is associated with rates of cognitive impairment in methamphetamine-dependent men with HIV: preliminary findings. J Neurovirol (2011) 0.86
The HAND Database: a gateway to understanding the role of HIV in HIV-associated neurocognitive disorders. BMC Med Genomics (2015) 0.85
Genome-wide association study of neurocognitive impairment and dementia in HIV-infected adults. Am J Med Genet B Neuropsychiatr Genet (2012) 0.84
PrPC, the cellular isoform of the human prion protein, is a novel biomarker of HIV-associated neurocognitive impairment and mediates neuroinflammation. Am J Pathol (2010) 0.84
Neurologic Complications and Considerations in HIV-Infected Persons. Curr Infect Dis Rep (2013) 0.83
Facial emotion recognition impairments in individuals with HIV. J Int Neuropsychol Soc (2010) 0.83
Neurocognitive deficits in HIV-infected women and victims of childhood trauma. AIDS Care (2012) 0.82
Prevalence and factors associated with probable HIV dementia in an African population: a cross-sectional study of an HIV/AIDS clinic population. BMC Psychiatry (2013) 0.82
Altered functional response to risky choice in HIV infection. PLoS One (2014) 0.81
Recent clinical history and cognitive dysfunction for attention and executive function among human immunodeficiency virus-infected patients. Arch Clin Neuropsychol (2011) 0.80
Screening for Neurocognitive Impairment in HIV-Infected Individuals at First Contact after HIV Diagnosis: The Experience of a Large Clinical Center in Northern Italy. Int J Mol Sci (2016) 0.79
HIV-1 Tat activates a RhoA signaling pathway to reduce NMDA-evoked calcium responses in hippocampal neurons via an actin-dependent mechanism. J Neurochem (2014) 0.79
Training needs and evaluation of a neuro-HIV training module for non-physician healthcare workers in western Kenya. J Neurol Sci (2011) 0.79
Evidence-based treatment for HIV-associated dementia and cognitive impairment: why so little? PLoS Clin Trials (2007) 0.76
Cross-sectional study of unexplained white matter lesions in HIV positive individuals undergoing brain magnetic resonance imaging. AIDS Patient Care STDS (2014) 0.75
Routine detection and management of neurocognitive impairment in HIV-positive patients in a UK centre. Int J STD AIDS (2013) 0.75
Validation of the International HIV Dementia Scale as a Screening Tool for HIV-Associated Neurocognitive Disorders in a German-Speaking HIV Outpatient Clinic. PLoS One (2016) 0.75
Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr (2007) 4.30
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis (2011) 3.59
Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr (2002) 3.55
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol (2011) 2.80
Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2002) 2.45
Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. AIDS (2011) 2.45
Rate of CD4+ cell count increase over periods of viral load suppression: relationship with the number of previous virological failures. Clin Infect Dis (2010) 2.32
Delayed presentation and late testing for HIV: demographic and behavioral risk factors in a multicenter study in Italy. J Acquir Immune Defic Syndr (2004) 2.22
Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort. J Infect Dis (2004) 2.21
Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med (2002) 2.20
The extraordinary ligand binding properties of human serum albumin. IUBMB Life (2005) 2.00
Massively parallel pyrosequencing highlights minority variants in the HIV-1 env quasispecies deriving from lymphomonocyte sub-populations. Retrovirology (2009) 1.99
Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics (2004) 1.98
Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza. Emerg Infect Dis (2008) 1.98
Relationship between HAART adherence and adipose tissue alterations. J Acquir Immune Defic Syndr (2002) 1.97
Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis. Clin Infect Dis (2009) 1.95
A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients. Antivir Ther (2002) 1.92
Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Ann Neurol (2008) 1.90
Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review. J Antimicrob Chemother (2007) 1.89
One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence (2010) 1.84
Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J Acquir Immune Defic Syndr (2009) 1.81
Seroprevalence of dengue infection: a cross-sectional survey in mainland Tanzania and on Pemba Island, Zanzibar. Int J Infect Dis (2011) 1.78
Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev (2009) 1.76
High HIV prevalence in male patients with acute hepatitis A in the Rome metropolitan area, Italy 2002-2008. J Hepatol (2011) 1.71
Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). J Neurovirol (2003) 1.70
Analysis of single-nucleotide polymorphisms (SNPs) in human CYP3A4 and CYP3A5 genes: potential implications for the metabolism of HIV drugs. BMC Med Genet (2014) 1.58
Accuracy of immunodiagnostic tests for active tuberculosis using single and combined results: a multicenter TBNET-Study. PLoS One (2008) 1.56
Anthrax toxin: a tripartite lethal combination. FEBS Lett (2002) 1.54
Neurocognitive impairment and survival in a cohort of HIV-infected patients treated with HAART. AIDS Res Hum Retroviruses (2005) 1.52
Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS (2002) 1.52
Post-exposure prophylaxis of HIV infection in healthcare workers: recommendations for the European setting. Eur J Epidemiol (2004) 1.50
Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. AIDS (2002) 1.48
Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels. Clin Infect Dis (2014) 1.47
Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance. J Infect Dis (2003) 1.47
Accuracy of malaria diagnosis by microscopy, rapid diagnostic test, and PCR methods and evidence of antimalarial overprescription in non-severe febrile patients in two Tanzanian hospitals. Am J Trop Med Hyg (2009) 1.47
Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. AIDS Res Hum Retroviruses (2002) 1.45
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update December 2014. New Microbiol (2015) 1.45
Isoniazid prophylaxis differently modulates T-cell responses to RD1-epitopes in contacts recently exposed to Mycobacterium tuberculosis: a pilot study. Respir Res (2007) 1.45
Neuroactive antiretroviral drugs do not influence neurocognitive performance in less advanced HIV-infected patients responding to highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2006) 1.41
Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy. Clin Infect Dis (2004) 1.40
Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. AIDS (2005) 1.37
Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure. AIDS (2004) 1.37
Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. Clin Infect Dis (2005) 1.35
Epidemiology of viral hepatitis infections in an area of southern Italy with high incidence rates of liver cancer. Eur J Cancer (2008) 1.33
Framework for the design and operation of high-level isolation units: consensus of the European Network of Infectious Diseases. Lancet Infect Dis (2009) 1.32
Ebola viral load at diagnosis associates with patient outcome and outbreak evolution. J Clin Invest (2015) 1.30
Late presenters in new HIV diagnoses from an Italian cohort of HIV-infected patients: prevalence and clinical outcome. Antivir Ther (2011) 1.30
Neurocognitive performance and quality of life in patients with HIV infection. AIDS Res Hum Retroviruses (2003) 1.29